Biotech bubbleologists will be out in force following a rough month for the sector, which saw blue-chip companies developing new medicines collectively record their first reversal for more than 18 months.
Biotech bubbleologists will be out in force following a rough month for the sector, which saw blue-chip companies developing new medicines collectively record their first reversal for over 18 months.
Psoriasis is a serious immune-mediated inflammatory disease, but for patients it is much more. The condition brings with it a number of other co-morbidities that impact on patients’ lives perhaps more than many other serious chronic conditions. This is because psoriasis is also associated with concomitant psychosocial effects, and those with more severe disease are at a greater risk of death from heart disease and diabetes.
Boulder, Colo.-based Array Biopharma Inc. will be receiving a $5 million milestone payment following the announcement that Astrazeneca plc has begun a Phase III trial for selumetinib, an oral MEK inhibitor, being investigated as second-line therapy in patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive.
One of the burning topics that industry and academic scientists, policymakers and patients will be discussing this week at a one-day forum focused on the primary hurdles to combating Alzheimer’s disease (AD), sponsored by the Pharmaceutical Research and Manufacturers of America, the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation, will be how to accelerate the impact of pre-competitive collaborative partnerships to get products moving into clinical trials.
Mergers and acquisitions have always been a regular staple in the biotech industry. However, the speculation that a “land grab” for attractive and product rich biotechnology companies would gather steam in the third quarter has not panned out so far. In fact, the list of companies that investors are betting on that will be take-out targets remains longer than the actual number of consummated deals.
The World Alzheimer Report 2013 paints a chilling picture of the scope of the disease with more than 35 million people worldwide currently living with the condition, a number that is expected to double by 2030 and more than triple by 2050.
Remember the heady days about eight years ago when Amgen Inc. and Genentech Inc., prior to its acquisition by Basel, Switzerland-based Roche AG, both vied for top spot in terms of market capitalization? At that time, both companies briefly commanded impressive $100 billion market caps and their collective valuation represented a significant chunk of the whole sector’s worth. Between then and now the industry took a nose dive in the wake of cratering global financial markets. As a result valuations declined and Genentech, now a unit of Roche, no longer factors into the industry’s current performance statistics. Well, thanks to...
Continuing where they left off at the end of the second quarter, global biotechs recorded yet another positive quarter. However, the fundraising pace did slow down reflecting what proved to be a comparatively quiet summer period. Nevertheless, more than $4 billion was banked by public and private companies in the third quarter of 2013, a 29 percent drop from the almost $6 billion that was raised in the second quarter and 17 percent shy of the total generated in Q1 2013.
